Alternative methods for the diagnosis of macroprolactinemia: urine prolactin level and serum / urine prolactin ratio

Year 2019, Volume: 46 Issue: 1, 119 - 124, 03.03.2019

Zafer Pekkolay , Mazhar Müslüm Tuna Mehmet Güven Şadiye Altun Tuzcu İbrahim Kaplan Zeki Akkuş Alpaslan Kemal Tuzcu

https://doi.org/10.5798/dicletip.534848

Abstract

Objective:
The aim of this study was to investigate the urine prolactin and serum/urine
prolactin ratio for accuracy diagnosis of macroprolactinemia.

Methods: In
the retrospective cross-sectional analysis, prolactin levels (high or normal)
in the reproductive period of men and women were included in the study.
Polyethylene glycol (PEG) precipitation method was used for the detection of
macroprolactinemia. Then, patients were divided into three groups as
macroprolactinemia, prolactinoma and healthy control group. In patients,
prolactin values in spot urine with simultaneous serum prolactin values were
calculated. The non-parametric Kruskal-Wallis test was used to compare the
groups. The receiver-operating characteristic (ROC) curve was determined to
evaluate the predictive power of serum/urine prolactin ratio.

Results: A
total of 41 patients were included in the study. Female/male:36 (87.8%)/ 5
(12.2%). Urinary prolactin median(minimum-maximum) values were
macroprolactinemia, prolactinoma and control group, respectively;
0.06(0.05-0.10), 0.11(0.02-0.95), 0.08(0.05-0.25) ng/ml. Serum/urine ratio
median (minium-maximum) values were macroprolactinemia, prolactinoma, and control
group, respectively; 633(51-1032), 990(104-9635), 395.5(138-953). When the
groups were compared, the patients with prolactinoma had higher urinary
prolactin levels(p <0.01). Serum/urine prolactin ratio was found to be the
highest in prolactinoma patients and the lowest in the control group and a
significant difference was observed in groups (p <0.01).

ROC
analysis(control-macroprolactin) for serum/urine prolactin ratio (Sensitivity
84.6 specificity 93.7 cut off >549,5 AUC=0.83) p<0.01

Conclusion:
Urinary prolactin level and serum/urine prolactin ratio may be used in
diagnosis of macroprolactinemia.

Keywords

macroprolactinemia, urine prolactin

References

• 1. Horseman ND and Gregerson KA. Prolactin actions. Journal of Molecular Endocrinology. 2014; 52: 95-106.
• 2. Melmed S, Casanueva FF, Hoffman AR, et all. Endocrine Society. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011; 96: 273-88.
• 3. Freeman ME, Kanyicska B, Lerant A, et all. Prolactin: structure, function, and regulation of secretion. Physiological Reviews. 2000; 80: 1523–631.
• 4. Molitch ME. Prolactin in human reproduction In: Strauss JF, Barbieri R, eds. Yen and Jaffe's reproductive endocrinology: physiology, pathophysiology, and clinical management, 7th edn. Elsevier Saunders, Philadelphia 2014: 45-65.
• 5. Hattori N, Ishihara T, Saiki Y, et all. Macroprolactinaemia in patients with hyperprolactinaemia: composition of macroprolactin and stability during long-term follow-up. Clin Endocrinol (Oxf). 2010; 73: 792–7.
• 6. Hattori N, Nakayama Y, Kitagawa K, et all. Anti-prolactin (PRL) autoantibody-binding sites (epitopes) on PRL molecule in macroprolactinemia. Clin Endocrinol (Oxf). 2006; 190: 287-93.
• 7. Freeman ME, Kanyicska B, Lerant A, et all. Prolactin: structure, function, and regulation of secretion. Physiol Rev. 2000;80:1523–631.
• 8. Samson SL, Hamrahian AH, Ezzat S. American Association of Clinical Endocrinologists. American College of Endocrinology disease state clinical review: clinical relevance of macroprolactin in the absence or presence of true hyperprolactinemia. Endocr Pract. 2015; 21: 1427–35.
• 9. Hattori N, Ishihara T, Saiki Y, et all. Macroprolactinaemia in patients with hyperprolactinaemia: composition of macroprolactin and stability during long-term follow-up. Clinical Endocrinology. 2010; 73: 792–7.
• 10. Jamaluddin FA, Sthaneshwar P, Hussein Z, et all. Importance of screening for macroprolactin in all hyperprolactinaemic sera. Malays J Patho. 2013; 35: 59–63.
• 11. Leslie H, Courtney CH, Bell PM, et all. Laboratory and clinical experience in 55 patients with macroprolactinemia identified by a simple polyethylene glycol precipitation method. J Clin Endocrinol Metab. 2001; 86: 2743-6.
• 12. Silva AM, Costa da PM, Pacheco A, et all. Assessment of macroprolactinemia by polyethylene glycol precipitation method. Revista Portuguesa de Endocrinologia, Diabetes e Metabolismo 2014; 9: 25-28.
• 13. Snyder PJ, Causes of hyperprolactinemia. https://www.uptodate.com/contents/causes of hyperprolactinemia.
• 14. Smith TP, Kavanagh L, Healy ML, et all. Technology insight: measuring prolactin in clinical samples. Nature Reviews Endocrinology. 2007; 3: 279-89.
• 15. Coppedge RL , Segaloff A. Urinary Prolactin Excretion In Man, The Journal Of Clinical Endocrinology & Metabolism. 1951; 11: 465–76.
• 16. Leaños-Miranda A, Márquez-Acosta J, Cárdenas-Mondragón GM, et all. Urinary prolactin as a reliable marker for preeclampsia, its severity, and the occurrence of adverse pregnancy outcomes. J Clin Endocrinol Metab. 2008; 93: 2492-9.
• 17. Keely EJ, Charles F. Measurement of human urinary prolactin as a noninvasive study tool. Clinical chemistry. 1994; 40: 2017-21.